Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$103.91 USD

103.91
8,283,452

-0.74 (-0.71%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $103.92 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing

Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.

    Cardiovascular Systems Rides on New Products Amid Tight Race

    Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.

      Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?

      Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?

        Both Merck and Pfizer reported upbeat first-quarter results on May 1

          Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates

          Universal Health (UHS) posts a solid Q1 driven by higher revenues.

            Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance

            Strong performance across segments supports Anthem's (ANTM) first-quarter results.

              Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered

              Centene (CNC) delivers strong first-quarter results on the back of significant membership growth.

                The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

                The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive

                  Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained

                  Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.

                    MS, USB, ABT & TXT Leads Q1 Earnings

                    MS, USB, ABT & TXT Leads Q1 Earnings

                      Mark Vickery headshot

                      Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT

                      We are still in the early stages so far, but overall results have been notably better than expected.

                        Abbott (ABT) Beats on Earnings and Revenues in Q1

                        Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.

                          Tracey Ryniec headshot

                          5 Amazing Earnings Charts This Week

                          It's not easy to beat the estimate nearly every quarter for years. But these 5 companies are doing it.

                            Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?

                            Strong revenue opportunity from various Oncology and Imaging Component products is likely to drive Varian Medical (VAR) in Q2.

                              Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

                              Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

                                Benjamin Rains headshot

                                3 Stocks to Buy Ahead of Earnings

                                Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.

                                  Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

                                  Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.

                                    Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?

                                    Intuitive Surgical's (ISRG) developments on the da Vinci platform are a positive, while intense competition raises concern.

                                      Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?

                                      Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.

                                        Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?

                                        Abbott (ABT) poised to ride high on strength in EPD business in Q1.

                                          Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?

                                          Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.

                                            Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?

                                            Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.

                                              Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device

                                              Abbott (ABT) adopts ways to strengthen Heart Failure business under the Medical Device segment.

                                                Urmimala Biswas headshot

                                                Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire

                                                Chances of a retaliation from China leads to widespread losses in the medical device sector.

                                                  Edwards (EW) Completes Enrollment for PARTNER 3 Sub-Study

                                                  Edwards' (EW) near-term product pipeline looks quite encouraging.